224 related articles for article (PubMed ID: 27042030)
1. Effectiveness and safety of oxycodone/naloxone in the management of chronic pain in patients with systemic sclerosis with recurrent digital ulcers: two case reports.
Ughi N; Crotti C; Ingegnoli F
Clin Interv Aging; 2016; 11():307-11. PubMed ID: 27042030
[TBL] [Abstract][Full Text] [Related]
2. Is oxycodone/naloxone effective and safe in managing chronic pain of a fragile elderly patient with multiple skin ulcers of the lower limbs? A case report.
Guerriero F; Maurizi N; Francis M; Sgarlata C; Ricevuti G; Rondanelli M; Perna S; Rollone M
Clin Interv Aging; 2015; 10():1283-7. PubMed ID: 26300632
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis.
Lazzari M; Greco MT; Marcassa C; Finocchi S; Caldarulo C; Corli O
Drug Des Devel Ther; 2015; 9():5863-72. PubMed ID: 26586937
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and gastrointestinal tolerability of oral oxycodone/naloxone combination for chronic pain in outpatients with cancer: an observational study.
Cuomo A; Russo G; Esposito G; Forte CA; Connola M; Marcassa C
Am J Hosp Palliat Care; 2014 Dec; 31(8):867-76. PubMed ID: 24249829
[TBL] [Abstract][Full Text] [Related]
5. Quality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone/naloxone.
Morlion B; Clemens KE; Dunlop W
Clin Drug Investig; 2015 Jan; 35(1):1-11. PubMed ID: 25479959
[TBL] [Abstract][Full Text] [Related]
6. Oral oxycodone/naloxone for pain control in cirrhosis: Observational study in patients with symptomatic metastatic hepatocellular carcinoma.
Tovoli F; De Lorenzo S; Samolsky Dekel BG; Piscaglia F; Benevento F; Brandi G; Bolondi L
Liver Int; 2018 Feb; 38(2):278-284. PubMed ID: 28792650
[TBL] [Abstract][Full Text] [Related]
7. Switching to low-dose oral prolonged-release oxycodone/naloxone from WHO-Step I drugs in elderly patients with chronic pain at high risk of early opioid discontinuation.
Lazzari M; Marcassa C; Natoli S; Carpenedo R; Caldarulo C; Silvi MB; Dauri M
Clin Interv Aging; 2016; 11():641-9. PubMed ID: 27257377
[TBL] [Abstract][Full Text] [Related]
8. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain.
Vondrackova D; Leyendecker P; Meissner W; Hopp M; Szombati I; Hermanns K; Ruckes C; Weber S; Grothe B; Fleischer W; Reimer K
J Pain; 2008 Dec; 9(12):1144-54. PubMed ID: 18708300
[TBL] [Abstract][Full Text] [Related]
9. Combined oral prolonged-release oxycodone and naloxone in chronic pain management.
Mercadante S; Giarratano A
Expert Opin Investig Drugs; 2013 Jan; 22(1):161-6. PubMed ID: 23215628
[TBL] [Abstract][Full Text] [Related]
10. Oxycodone/naloxone preparation can cause acute withdrawal symptoms when misused parenterally or taken orally.
Wong A; Macleod D; Robinson J; Koutsogiannis Z; Graudins A; Greene SL
Clin Toxicol (Phila); 2015; 53(8):815-8. PubMed ID: 26109423
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, 12-month, open-label, single-arm safety study of oxycodone-hydrochloride/naltrexone-hydrochloride extended-release capsules (ALO-02) in patients with moderate-to-severe chronic noncancer pain.
Arora S; Setnik B; Michael D; Hudson JD; Clemmer R; Meisner P; Pixton GC; Goli V; Sommerville KW
J Opioid Manag; 2014; 10(6):423-36. PubMed ID: 25531960
[TBL] [Abstract][Full Text] [Related]
12. Developments in managing severe chronic pain: role of oxycodone-naloxone extended release.
Fanelli G; Fanelli A
Drug Des Devel Ther; 2015; 9():3811-6. PubMed ID: 26229442
[TBL] [Abstract][Full Text] [Related]
13. Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain - results from a large observational study.
Hermanns K; Junker U; Nolte T
Expert Opin Pharmacother; 2012 Feb; 13(3):299-311. PubMed ID: 22224497
[TBL] [Abstract][Full Text] [Related]
14. The attractiveness of opposites: agonists and antagonists.
O'Brien T
J Pain Palliat Care Pharmacother; 2015 Mar; 29(1):67-9. PubMed ID: 25643224
[TBL] [Abstract][Full Text] [Related]
15. Digital ulcer debridement in systemic sclerosis: a systematic literature review.
Hughes M; Alcacer-Pitarch B; Gheorghiu AM; Praino E; Sandler RD; Tavor Y; Bruni C; Matucci-Cerinic M
Clin Rheumatol; 2020 Mar; 39(3):805-811. PubMed ID: 31955323
[TBL] [Abstract][Full Text] [Related]
16. Bowel function during pain therapy with oxycodone/naloxone prolonged-release tablets in patients with advanced cancer.
Clemens KE; Quednau I; Klaschik E
Int J Clin Pract; 2011 Apr; 65(4):472-8. PubMed ID: 21401835
[TBL] [Abstract][Full Text] [Related]
17. Patient preference with respect to QoL and reduction in opioid-induced constipation (OIC) after treatment with prolonged-release (PR) oxycodone/naloxone compared with previous analgesic therapy [PREFER study].
van Dongen VC; Vanelderen PJ; Koopmans-Klein G; van Megen YJ; Van Zundert J; Huygen FJ
Int J Clin Pract; 2014 Nov; 68(11):1364-75. PubMed ID: 24853258
[TBL] [Abstract][Full Text] [Related]
18. A Practical Approach to the Management of Digital Ulcers in Patients With Systemic Sclerosis: A Narrative Review.
Hughes M; Allanore Y; El Aoufy K; Denton CP; Khanna D; Krieg T; Matucci-Cerinic M
JAMA Dermatol; 2021 Jul; 157(7):851-858. PubMed ID: 34037677
[TBL] [Abstract][Full Text] [Related]
19. A comparison of oxycodone prolonged-release vs. oxycodone + naloxone prolonged-release after laparoscopic hysterectomy.
Comelon M; Wisloeff-Aase K; Raeder J; Draegni T; Undersrud H; Qvigstad E; Bjerkelund CE; Lenz H
Acta Anaesthesiol Scand; 2013 Apr; 57(4):509-17. PubMed ID: 23301686
[TBL] [Abstract][Full Text] [Related]
20. Prolonged-release oxycodone/naloxone in nonmalignant pain: single-center study in patients with constipation.
Gatti A; Casali M; Lazzari M; Tufaro G; Gafforio P; Silvestri C; Marcassa C; Sabato AF
Adv Ther; 2013 Jan; 30(1):41-59. PubMed ID: 23269562
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
